Clinical Study

Nightingale: Clinical Utility Of Management Of Patients With Ct And Ldct Identified Pulmonary Nodules Using The Percepta Nasal Swab Classifier – With Familiarization.

Posted Date: Mar 12, 2023

  • Investigator: Christopher Radchenko
  • Specialties: Cancer, Lung Cancer
  • Type of Study: Device

To evaluate if use of the Percepta Nasal Swab test in the diagnostic work up of newly identified pulmonary nodules reduces the number of invasive procedures in the group classified as low-risk by the test and that are benign as compared to a control group managed without a Percepta Nasal Swab test result. To evaluate if use of the Percepta Nasal Swab test in the diagnostic work up of newly identified pulmonary nodules increases the proportion of subjects classified as high-risk by the test and have primary lung cancer that go directly to appropriate therapy as compared to a control group managed without a Percepta Nasal Swab test result.

Criteria:

Patient Who Presents With A Newly Identified Nodule =30 Mm On Ct. Patient Is A Current Or Former Cigarette Smoker (> 100 Cigarettes In A Lifetime). Patients Must Be Between 29 – 85 Years Of Age. Patients Do Not Have An Active Known Cancer (Other Than Non-Melanoma Skin Cancer) Or Prior History Of Lung Cancer (Patients With Prior Cancers Other Than Lung Cancer Are Eligible).

Keywords:

Nightingale, Lung Cancer, Lung Nodule

For More Information:

Elizabeth Hotel
NULL
hotelbh@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.